WO2018141313A3 - Uses of fgf-4 compounds - Google Patents
Uses of fgf-4 compounds Download PDFInfo
- Publication number
- WO2018141313A3 WO2018141313A3 PCT/CN2018/083256 CN2018083256W WO2018141313A3 WO 2018141313 A3 WO2018141313 A3 WO 2018141313A3 CN 2018083256 W CN2018083256 W CN 2018083256W WO 2018141313 A3 WO2018141313 A3 WO 2018141313A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fgf
- compounds
- prevention
- treatment
- specifically
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 101100446513 Mus musculus Fgf4 gene Proteins 0.000 title 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 abstract 2
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided are uses of FGF-4 compounds. More specifically, provided are uses of FGF-4 compounds in the prevention and/or treatment of metabolic disorders.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/083256 WO2018141313A2 (en) | 2018-04-17 | 2018-04-17 | Uses of fgf-4 compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/083256 WO2018141313A2 (en) | 2018-04-17 | 2018-04-17 | Uses of fgf-4 compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2018141313A2 WO2018141313A2 (en) | 2018-08-09 |
WO2018141313A9 WO2018141313A9 (en) | 2018-09-07 |
WO2018141313A3 true WO2018141313A3 (en) | 2019-02-21 |
Family
ID=63039362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/083256 WO2018141313A2 (en) | 2018-04-17 | 2018-04-17 | Uses of fgf-4 compounds |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018141313A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111944035B (en) * | 2019-05-14 | 2022-08-12 | 温州医科大学 | FGF4 and its applications |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003012053A2 (en) * | 2001-08-01 | 2003-02-13 | New York University | Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis |
WO2011158125A2 (en) * | 2010-06-17 | 2011-12-22 | Katholieke Universiteit Leuven | Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells |
CN102971001A (en) * | 2009-08-14 | 2013-03-13 | 阿勒根公司 | Methods of treating cancer using growth factor retargeted endopeptidases |
KR101490017B1 (en) * | 2013-03-14 | 2015-02-09 | 건국대학교 산학협력단 | Medium Composition for Establishing Novel Epiblast Stem Cell and Method for Establishing Novel Epiblast Stem Cell Using Thereof |
WO2015171928A2 (en) * | 2014-05-07 | 2015-11-12 | Joslin Diabetes Center, Inc. | Methods and compositions for induction of ucp1 expression |
-
2018
- 2018-04-17 WO PCT/CN2018/083256 patent/WO2018141313A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003012053A2 (en) * | 2001-08-01 | 2003-02-13 | New York University | Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis |
CN102971001A (en) * | 2009-08-14 | 2013-03-13 | 阿勒根公司 | Methods of treating cancer using growth factor retargeted endopeptidases |
WO2011158125A2 (en) * | 2010-06-17 | 2011-12-22 | Katholieke Universiteit Leuven | Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells |
KR101490017B1 (en) * | 2013-03-14 | 2015-02-09 | 건국대학교 산학협력단 | Medium Composition for Establishing Novel Epiblast Stem Cell and Method for Establishing Novel Epiblast Stem Cell Using Thereof |
WO2015171928A2 (en) * | 2014-05-07 | 2015-11-12 | Joslin Diabetes Center, Inc. | Methods and compositions for induction of ucp1 expression |
Also Published As
Publication number | Publication date |
---|---|
WO2018141313A2 (en) | 2018-08-09 |
WO2018141313A9 (en) | 2018-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019227085A8 (en) | Designed bacterial compositions and uses thereof | |
IL312607A (en) | Interleukin-21 muteins and methods of treatment | |
EP4445954A3 (en) | Cellular models of and therapies for ocular diseases | |
WO2019209962A8 (en) | Compounds and uses thereof | |
CA2956871C (en) | Compounds active towards bromodomains | |
WO2017218949A3 (en) | Peptidomimetic macrocycles and uses thereof | |
WO2016172658A3 (en) | Microbiome regulators and related uses thereof | |
IL291445A (en) | Bacterial strains, their compositions and their use for the treatment of gastrointestinal disorders | |
WO2018019823A8 (en) | Administration and dosage of diaminophenothiazines | |
WO2017136450A3 (en) | Compounds and methods of treating rna-mediated diseases | |
WO2017106364A3 (en) | Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13 | |
WO2017156495A8 (en) | Compounds and methods for modulating bruton's tyrosine kinase | |
WO2019209948A8 (en) | Compounds and uses thereof | |
EP4316592A3 (en) | Carbamoyl phenylalaninol compounds and uses thereof | |
WO2018178243A3 (en) | Dihydrotetrabenazine for use in the treatment a movement disorder | |
EP4424368A3 (en) | Compositions comprising an urolithin compound | |
WO2015106215A3 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
WO2020154571A8 (en) | Compounds and uses thereof | |
WO2019071021A3 (en) | Immunomodulatory oligosaccharides | |
WO2016130581A3 (en) | Combination cancer therapy | |
WO2016181220A3 (en) | Therapeutic compositions comprising a combination from a curcumin, a harmine and isovanillin component and methods of use thereof | |
WO2016127123A3 (en) | Compounds and methods for preventing or treating sensory hair cell death | |
WO2019026065A3 (en) | Novel braf inhibitors and use thereof for treatment of cutaneous reactions | |
EP4331683A3 (en) | Methods and compositions for the treatment of hair loss | |
WO2019098811A3 (en) | Composition for preventing, alleviating, or treating bone loss diseases, comprising cyclo(his-pro) (chp) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18747641 Country of ref document: EP Kind code of ref document: A2 |